Kisspeptin Research Overview

Kisspeptin is a neuropeptide encoded by the KISS1 gene, produced primarily in neurons of the hypothalamus. Since the early 2000s it has been recognized as the most proximal endogenous activator of gonadotropin-releasing hormone (GnRH) secretion, placing it at the top of the hypothalamic-pituitary-gonadal (HPG) axis. Research interest has grown substantially because of its potential to probe and modulate reproductive physiology without replacing hormones directly. The Dhillo group at Imperial College London has produced much of the human pharmacology data accumulated to date.

What Is Kisspeptin?

Kisspeptin refers to a family of peptide fragments produced by cleavage of the 145-amino-acid KISS1 precursor protein. The most abundant circulating isoform in humans is kisspeptin-54, though shorter forms — kisspeptin-14, kisspeptin-13, and kisspeptin-10 — also retain biological activity at the kisspeptin receptor (KISS1R, also called GPR54). All isoforms share a conserved C-terminal decapeptide sequence that is required for receptor binding.

Kisspeptin-secreting neurons are concentrated in two hypothalamic nuclei: the anteroventral periventricular nucleus (AVPV) and the arcuate nucleus (ARC). The ARC neurons co-express kisspeptin, neurokinin B, and dynorphin — a triad termed KNDy neurons — which are thought to generate the pulsatile GnRH signal that drives downstream pituitary and gonadal function. KISS1R is expressed on GnRH neurons, and genetic disruption of either KISS1 or KISS1R in rodents and humans causes profound hypogonadotropic hypogonadism.

As a research compound, kisspeptin is sold as a lyophilized powder intended for laboratory use. It is not approved by the FDA or any comparable regulatory authority for clinical use.

Mechanism of Action

Kisspeptin binds KISS1R, a Gq/11-coupled G-protein-coupled receptor. Receptor activation triggers phospholipase C-mediated increases in intracellular calcium and protein kinase C signaling in GnRH neurons. This rapidly promotes GnRH release into the hypothalamo-pituitary portal blood, which in turn stimulates pituitary gonadotrophs to secrete luteinizing hormone (LH) and, to a lesser degree, follicle-stimulating hormone (FSH). The LH surge induced by kisspeptin closely mirrors the preovulatory LH surge in females.

Negative feedback from gonadal steroids — estrogen, progesterone, and testosterone — acts partly through kisspeptin neurons. In females, estradiol exerts dual effects: tonic negative feedback via ARC KNDy neurons suppresses basal GnRH pulsatility, while a positive feedback signal through AVPV kisspeptin neurons is proposed to trigger the mid-cycle LH surge. This bidirectional steroid gating makes kisspeptin a key integration point between peripheral gonadal status and central reproductive drive.

What the Research Shows

Dhillo et al. (2005) published the first demonstration that intravenous kisspeptin-54 potently stimulated LH, FSH, and testosterone in healthy men. Doses of 0.4–12.8 nmol/kg produced dose-dependent increases in LH within 30 minutes, establishing the HPG-axis activating capability of exogenous kisspeptin in humans (PMID 15994431).

Jayasena et al. (2014) provided proof of concept for a fertility application: a single subcutaneous injection of kisspeptin-54 triggered oocyte maturation in women undergoing IVF, with mature oocyte and embryo rates comparable to standard hCG trigger. This was notable because kisspeptin's physiological mechanism avoids the pharmacological overstimulation associated with hCG, potentially lowering risk of ovarian hyperstimulation syndrome (OHSS).

Abbara et al. (2017) conducted a Phase 2 randomized controlled trial enrolling 60 women at high risk of OHSS. Participants received a second dose of kisspeptin-54 after the initial trigger. The second dose improved oocyte maturation rates, with biochemical pregnancy, clinical pregnancy, and live birth rates per transfer of 63%, 53%, and 45%, respectively, across dose groups. Results were encouraging but the trial was small and open-label for dose adaptation.

Kisspeptin has also been studied in hypothalamic amenorrhea — a functional reproductive suppression common in athletes and women with low energy availability. Repeated subcutaneous dosing over several weeks has been shown to partially restore pulsatile LH release in this context, though effect sizes are modest and the optimal protocol has not been established. Research is also exploring kisspeptin analogs with longer half-lives and KISS1R small-molecule agonists.

Pharmacokinetics

Kisspeptin-54 is rapidly degraded by circulating endopeptidases and neprilysin. After intravenous administration, plasma half-life has been estimated at approximately 28–29 minutes in human studies. Subcutaneous administration produces a slower absorption profile, with peak plasma concentrations typically observed at 30–60 minutes post-injection and a correspondingly prolonged but attenuated pharmacodynamic response. The shorter isoforms (kisspeptin-10, -13, -14) are cleared even faster. No oral bioavailability data in humans exists; as a peptide, kisspeptin is expected to undergo rapid gastrointestinal proteolysis.

Reported Research Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

In published human trials, kisspeptin-54 has been administered intravenously at 0.4–12.8 nmol/kg for acute stimulation of LH release. For IVF trigger protocols, single subcutaneous doses in the range of 3.2–12.8 nmol/kg have been evaluated. Repeated subcutaneous dosing for hypothalamic amenorrhea has used approximately 1.28 nmol/kg twice weekly over 8 weeks in one study. Kisspeptin-10 has been used in experimental settings at doses of 1 nmol/kg IV as a shorter-duration stimulus. All these figures are from controlled clinical research protocols and represent population-level observations, not guidance for any individual.

Storage and Handling

As a lyophilized peptide, kisspeptin should be stored at -20 °C and protected from moisture and light. Once reconstituted in bacteriostatic or sterile water, solutions should be kept at 2–8 °C and used within 28 days. Repeated freeze-thaw cycles accelerate degradation. All handling should be performed under sterile conditions in an appropriate laboratory setting.

What Kisspeptin Is NOT

Kisspeptin is not an approved fertility drug, hormone therapy, or testosterone booster. It has not received regulatory approval from the FDA, EMA, or any comparable agency for any indication. Claims that kisspeptin reliably increases testosterone, reverses hypogonadism, or functions as an alternative to TRT in humans are not supported by controlled clinical data. The research base is promising but still Phase 1/2. Kisspeptin is not a growth hormone secretagogue, not a GnRH analog, and is distinct from LH or FSH in its mechanism.

References

1. Dhillo WS et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609–6615. PMID 15994431.

2. Jayasena CN et al. Kisspeptin: a novel physiological trigger for oocyte maturation in IVF treatment. Lancet. 2014;383(9925):1361–1362.

3. Abbara A et al. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. Hum Reprod. 2017;32(9):1915–1924. PMID 28854728.

4. Pinilla L et al. Kisspeptins and reproduction: physiological roles and regulatory mechanisms. Physiol Rev. 2012;92(3):1235–1316.